Oncopeptides AB Registered Shs News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

15.02.23	Ausblick: Oncopeptides Registered verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net)
01.02.23	Erste Schätzungen: Oncopeptides Registered vermeldet Zahlen zum jüngsten Quartal (finanzen.net)
08.11.22	Ausblick: Oncopeptides Registered legt Zahlen zum jüngsten Quartal vor (finanzen.net)
25.10.22	Erste Schätzungen: Oncopeptides Registered gewährt Anlegern Blick in die Bücher (finanzen.net)
10.08.22	Ausblick: Oncopeptides Registered zieht Bilanz zum jüngsten Jahresviertel (finanzen.net)
27.07.22	Erste Schätzungen: Oncopeptides Registered legt Zahlen zum jüngsten Quartal vor (finanzen.net)
03.05.22	Ausblick: Oncopeptides Registered stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net)
19.04.22	Erste Schätzungen: Oncopeptides Registered vermeldet Zahlen zum jüngsten Quartal (finanzen.net)
26.05.21	Bulletin from the Annual General Meeting in Oncopeptides AB (publ) (PR Newswire)
26.05.21	Bulletin from the Annual General Meeting in Oncopeptides AB (publ) (PR Newswire)
26.05.21	Oncopeptides publishes report for Q1 2021 and updated dates for the publication of the reports for Q2 and Q3 2021 (PR Newswire)
26.05.21	Oncopeptides publishes report for Q1 2021 and updated dates for the publication of the reports for Q2 and Q3 2021 (PR Newswire)
25.05.21	Oncopeptides AB: Phase 3 OCEAN study demonstrates that melflufen is at least as efficacious as pomalidomide, the most used medicine in relapsed refractory multiple myeloma (PR Newswire)
25.05.21	Oncopeptides AB: Phase 3 OCEAN study demonstrates that melflufen is at least as efficacious as pomalidomide, the most used medicine in relapsed refractory multiple myeloma (PR Newswire)
20.05.21	Oncopeptides AB: Invitation to presentation of the Q1 2021 results (PR Newswire)
20.05.21	Oncopeptides AB: Invitation to presentation of the Q1 2021 results (PR Newswire)
20.05.21	Oncopeptides presents clinical abstracts on melflufen at the 2021 American Society of Clinical Oncology (PR Newswire)
20.05.21	Oncopeptides presents clinical abstracts on melflufen at the 2021 American Society of Clinical Oncology (PR Newswire)
12.05.21	Oncopeptides presents new clinical and preclinical melflufen data at the upcoming European Hematology Association meeting (PR Newswire)
12.05.21	Oncopeptides presents new clinical and preclinical melflufen data at the upcoming European Hematology Association meeting (PR Newswire)
05.05.21	Oncopeptides completes patient enrollment in phase 2 PORT study (PR Newswire)
05.05.21	Oncopeptides completes patient enrollment in phase 2 PORT study (PR Newswire)
30.04.21	Number of shares and votes in Oncopeptides (PR Newswire)
30.04.21	Number of shares and votes in Oncopeptides (PR Newswire)
26.04.21	Oncopeptides publishes the 2020 Annual Report (PR Newswire)
26.04.21	Oncopeptides publishes the 2020 Annual Report (PR Newswire)
26.04.21	Annual General Meeting in Oncopeptides AB (publ) (PR Newswire)
26.04.21	Annual General Meeting in Oncopeptides AB (publ) (PR Newswire)
16.04.21	Oncopeptides submits application for conditional marketing authorization of melflufen in the EU (PR Newswire)
16.04.21	Oncopeptides submits application for conditional marketing authorization of melflufen in the EU (PR Newswire)
31.03.21	Number of shares and votes in Oncopeptides (PR Newswire)
31.03.21	Number of shares and votes in Oncopeptides (PR Newswire)
22.03.21	Oncopeptides announces that PEPAXTO® is included in new Multiple Myeloma guidelines of National Comprehensive Cancer Network® (PR Newswire)
22.03.21	Oncopeptides announces that PEPAXTO® is included in new Multiple Myeloma guidelines of National Comprehensive Cancer Network® (PR Newswire)
22.03.21	Oncopeptides Announces National Comprehensive Cancer Network® Adds PEPAXTO® (melphalan flufenamide) to Its Multiple Myeloma Clinical Practice Guidelines (PR Newswire)
15.03.21	Oncopeptides announces that the first patients in the United States are being treated with PEPAXTO® (PR Newswire)
15.03.21	Oncopeptides announces that the first patients in the United States are being treated with PEPAXTO® (PR Newswire)
08.03.21	Oncopeptides strengthens leadership in Europe and opens an Early Access Program in multiple myeloma (PR Newswire)
08.03.21	Oncopeptides strengthens leadership in Europe and opens an Early Access Program in multiple myeloma (PR Newswire)
01.03.21	FDA Approves Oncopeptides´ PEPAXTO® (melphalan flufenamide) for Patients with Triple-Class Refractory Multiple Myeloma (PR Newswire)
27.02.21	FDA approves Oncopeptides' PEPAXTO® ( melphalan flufenamide) for patients with relapsed or refractory multiple myeloma (PR Newswire)
27.02.21	FDA approves Oncopeptides' PEPAXTO® ( melphalan flufenamide) for patients with relapsed or refractory multiple myeloma (PR Newswire)
18.02.21	Oncopeptides AB: Year-end Report 2020 (PR Newswire)
18.02.21	Oncopeptides AB: Year-end Report 2020 (PR Newswire)
21.12.20	Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myeloma (PR Newswire)
21.12.20	Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myeloma (PR Newswire)
15.12.20	Oncopeptides strengthens its organization by appointing Linda Holmström as Director of Investor Relations (PR Newswire)
15.12.20	Oncopeptides strengthens its organization by appointing Linda Holmström as Director of Investor Relations (PR Newswire)
10.12.20	Full data set of Oncopeptides phase 2 HORIZON study in multiple myeloma published in the Journal of Clinical Oncology (PR Newswire)
10.12.20	Full data set of Oncopeptides phase 2 HORIZON study in multiple myeloma published in the Journal of Clinical Oncology (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Oncopeptides AB Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten